StemCell Therapy

iShares Nasdaq Biotechnology Index Fund (IBB) traded higher in the last at $284.75, gaining 0.19 points or 0.07%. From the data available, it can be said that the stock did not make an impact in the money flow department with the net figure coming to be $(-2.92) million. The composite uptick value of $19.32 million was eclipsed by the accrued downtick value of $22.25 million, thereby ensuring the up/down ratio of 0.87. For the week, the shares have posted returns of 0.6%.

iShares Nasdaq Biotechnology is having a Relative Strength Index of 61.82 which indicates the stock is not yet over sold or over bought based on the technical indicators.

Based on the Stock Research reports from financial advisors, there are Analysts recommending as a Strong Buy, and Analysts recommending as a Moderate Buy. Investors should also note that Stock brokerage firms are recommending to Hold the stock for short term. Stock Research experts are recommending to Sell based on the growth. There are Analysts recommending as a Strong Sell.

iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) witnessed a decline in the market cap on Friday as its shares dropped 0.07% or 0.19 points. After the session commenced at $284.48, the stock reached the higher end at $285.88 while it hit a low of $283.55. With the volume soaring to 764,100 shares, the last trade was called at $284.37. The company has a 52-week high of $301.8. The company has a market cap of $8,332 million and there are 29,300,000 shares in outstanding. The 52-week low of the share price is $240.3.

The ISHARES NASDAQ BIOTECHNOLOGY INDEX FUND seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of companies primarily engaged in the biotechnology industry, as represented by the NASDAQ Biotechnology Index.

Originally posted here:
Large Outflow of Money Witnessed in iShares Nasdaq ... - Highland Mirror

This entry was posted on February 13, 2017 at 2:43 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |